https://scholars.lib.ntu.edu.tw/handle/123456789/540620
Title: | Chronic viral hepatitis signifies the association of premixed insulin analogues with liver cancer risks: A nationwide population-based study | Authors: | CHIEN-HSIEH CHIANG KUO-CHIN HUANG Kuo C.-S. WAN-WAN LIN Su J.-H. Chen J.-D. |
Issue Date: | 2019 | Publisher: | MDPI AG | Journal Volume: | 16 | Journal Issue: | 12 | Start page/Pages: | 2097 | Source: | International Journal of Environmental Research and Public Health | Abstract: | This study sought to determine whether chronic hepatitis B or C would modify the association between insulin analogues and hepatocellular carcinoma (HCC) risks. We conducted a nationwide nested case-control study for HCC cases and matched controls from 2003 to 2013 among newly diagnosed type 2 diabetes patients on any antidiabetic agents in Taiwan before and after exclusion of chronic viral hepatitis, respectively. A total of 5832 and 1237 HCC cases were identified before and after exclusion of chronic viral hepatitis, respectively. Incident HCC risks were positively associated with any use of premixed insulin analogues (adjusted odds ratio (OR), 1.27; 95% CI 1.04 to 1.55) among total participants, especially among current users (adjusted OR, 1.45; 95% CI 1.12 to 1.89). However, the association between HCC occurrence and premixed insulin analogues diminished among participants without chronic viral hepatitis (adjusted OR, 1.35; 95% CI 0.92 to 1.98). We also observed a significant multiplicative interaction between chronic viral hepatitis and premixed insulin analogues on HCC risks (P = 0.010). Conclusions: Chronic viral hepatitis signifies the role of premixed insulin analogues in HCC oncogenesis. We recommend a closer liver surveillance among patients prescribed premixed insulin analogues with concomitant chronic viral hepatitis. ? 2019 by the authors. Licensee MDPI, Basel, Switzerland. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068010659&doi=10.3390%2fijerph16122097&partnerID=40&md5=deb24368eea0be50489b888f1f089ca0 https://scholars.lib.ntu.edu.tw/handle/123456789/540620 |
ISSN: | 1661-7827 | DOI: | 10.3390/ijerph16122097 | SDG/Keyword: | antidiabetic agent; beta adrenergic receptor blocking agent; diuretic agent; fibric acid derivative; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin derivative; insulin derivative; cancer; developing world; disease prevalence; health risk; hepatitis; hormone; adult; aged; Article; cancer incidence; cancer risk; case control study; Charlson Comorbidity Index; chronic hepatitis B; chronic hepatitis C; chronic kidney failure; cohort analysis; controlled study; disease association; female; heart failure; human; liver carcinogenesis; liver cell carcinoma; liver cirrhosis; major clinical study; male; national health insurance; non insulin dependent diabetes mellitus; population research; risk factor; very elderly; chronic hepatitis B; chronic hepatitis C; liver cell carcinoma; liver tumor; middle aged; non insulin dependent diabetes mellitus; Taiwan; Taiwan; Hepatitis C virus; Aged; Carcinoma, Hepatocellular; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulins; Liver Neoplasms; Male; Middle Aged; Taiwan |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.